May 19, 2020 / 06:30PM GMT
Kennen B. MacKay - RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi. My name is Kennen MacKay. I'm one of the senior biotechnology analysts here at RBC, and it's my great pleasure to kick off this next session with Exelixis. And from Exelixis. I'm joined by Dr. Mike Morrissey, the President and Chief Executive Officer.
Mike, thanks so much for joining this afternoon.
Michael M. Morrissey - Exelixis, Inc. - CEO, President & Director
How you're doing today? Glad to be on the call with you virtually, not the same as being in New York, but not bad either. So hope you're doing good.
Questions and Answers:
Kennen B. MacKay - RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology ResearchThanks, Mike. Likewise. So maybe it seems like Exelixis is really firing on all cylinders now, both commercially and clinically with some really very impressive data sets out recently. And I'd love to get to those. But first, cabo really surprised to the
Trustpilot
